Development of Shared Neoantigen Vaccines for Off-the-Shelf Cancer Therapy
- Machine learning prediction of shared neoantigens combined with potent viral vector delivery platforms was applied to the development of a cancer vaccine for the treatment of patients with advanced stage solid tumors
- Clinical and translational data from a Phase 1/2 trial will be presented with learnings applied from “bench to bedside and back to bench” studies to optimize shared neoantigen vaccines